Lantheus (NASDAQ:LNTH) Cut to Hold at StockNews.com

Lantheus (NASDAQ:LNTH) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

A number of other equities analysts also recently commented on the stock. Truist Financial restated a “buy” rating and set a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. B. Riley increased their price target on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. JMP Securities lowered their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. Finally, Redburn Atlantic began coverage on Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and a consensus target price of $122.50.

Lantheus Trading Up 3.7 %

NASDAQ:LNTH opened at $90.52 on Thursday. The stock’s 50 day simple moving average is $103.43 and its 200-day simple moving average is $96.53. Lantheus has a 12-month low of $50.20 and a 12-month high of $126.89. The firm has a market cap of $6.29 billion, a P/E ratio of 15.06 and a beta of 0.51.

Institutional Investors Weigh In On Lantheus

Several institutional investors have recently modified their holdings of the company. Hohimer Wealth Management LLC acquired a new position in shares of Lantheus during the 3rd quarter worth approximately $250,000. Coldstream Capital Management Inc. acquired a new stake in shares of Lantheus during the 3rd quarter worth $230,000. Geode Capital Management LLC raised its holdings in shares of Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after purchasing an additional 32,551 shares during the period. M&T Bank Corp lifted its position in Lantheus by 40.4% during the third quarter. M&T Bank Corp now owns 6,847 shares of the medical equipment provider’s stock valued at $752,000 after buying an additional 1,969 shares in the last quarter. Finally, Groupama Asset Managment acquired a new position in shares of Lantheus during the 3rd quarter valued at $439,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.